PET/CT Imaging of NSCLC with a α
Animals
Antigens, Neoplasm
/ metabolism
Carcinoma, Non-Small-Cell Lung
/ diagnostic imaging
Cell Line, Tumor
Fluorodeoxyglucose F18
Gallium Radioisotopes
/ chemistry
Humans
Integrins
/ metabolism
Lung Neoplasms
/ diagnostic imaging
Mice, Inbred BALB C
Mice, Nude
Peptide Fragments
/ metabolism
Positron Emission Tomography Computed Tomography
Tissue Distribution
Non-small cell lung cancer
PET/CT scan
Peptide
[18F] FDG
[68Ga]SFITGv6
αvβ6 integrin
Journal
Molecular imaging and biology
ISSN: 1860-2002
Titre abrégé: Mol Imaging Biol
Pays: United States
ID NLM: 101125610
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
pubmed:
24
1
2019
medline:
30
5
2020
entrez:
24
1
2019
Statut:
ppublish
Résumé
Targeted therapies are regarded as promising approaches to increase 5-year survival rate of non-small cell lung cancer (NSCLC) patients. Here, we investigated the clinical value of the α Affinity and binding properties of [ In vitro experiments revealed a significant time-dependent SFITGv6 binding of up to 33 % to α Even if SFITGv6 demonstrates excellent affinity and specificity for α
Identifiants
pubmed: 30671741
doi: 10.1007/s11307-018-1296-6
pii: 10.1007/s11307-018-1296-6
doi:
Substances chimiques
Antigens, Neoplasm
0
Gallium Radioisotopes
0
Integrins
0
Peptide Fragments
0
SFITGv6 peptide
0
integrin alphavbeta6
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Gallium-68
98B30EPP5S
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
973-983Références
Mol Imaging Biol. 2014 Aug;16(4):567-77
pubmed: 24448825
J Nucl Med. 2017 Apr;58(4):671-677
pubmed: 27980050
J Nucl Med. 2018 Nov;59(11):1679-1685
pubmed: 29674419
J Nucl Med. 2013 Jul;54(7):1101-5
pubmed: 23670900
J Histochem Cytochem. 2002 Oct;50(10):1371-80
pubmed: 12364570
Annu Rev Med. 2003;54:73-87
pubmed: 12471176
Cancer Res. 2009 Jul 15;69(14):5843-50
pubmed: 19549907
J Nucl Med. 2014 Apr;55(4):559-64
pubmed: 24525209
Angew Chem Int Ed Engl. 2012 Dec 21;51(52):13136-9
pubmed: 23150222
J Nucl Med. 2015 May;56(5):784-90
pubmed: 25814519
Cancers (Basel). 2015 May 26;7(2):930-49
pubmed: 26018876
Semin Nucl Med. 2002 Apr;32(2):92-6
pubmed: 11965604
Clin Cancer Res. 2017 Aug 1;23(15):4170-4180
pubmed: 28468949
J Nucl Med. 1999 May;40(5):883-8
pubmed: 10319765
BioDrugs. 2005;19(3):145-63
pubmed: 15984900
Clin Exp Metastasis. 2014 Oct;31(7):841-51
pubmed: 25150423
Semin Nucl Med. 2015 Jul;45(4):268-81
pubmed: 26050655
PLoS One. 2013 Aug 09;8(8):e70452
pubmed: 23950939
Clin Cancer Res. 2012 Feb 1;18(3):839-49
pubmed: 22173551
J Nucl Med. 2014 Jun;55(6):989-94
pubmed: 24711651
Respiration. 2006;73(5):634-41
pubmed: 16679755
J Pathol. 2007 Jul;212(3):316-24
pubmed: 17503414
Theranostics. 2014 May 15;4(7):745-60
pubmed: 24883124
J Nucl Med. 2013 Dec;54(12):2146-52
pubmed: 24167080
Mol Pharm. 2014 Apr 7;11(4):1208-17
pubmed: 24524409
Histopathology. 2004 Sep;45(3):226-36
pubmed: 15330800
Nucl Med Biol. 2015 Dec;42(12):945-57
pubmed: 26341848
Eur J Nucl Med Mol Imaging. 2005 Sep;32(9):1026-32
pubmed: 15877227
Cancer Res. 2007 Jun 15;67(12):5889-95
pubmed: 17575158
Eur J Nucl Med Mol Imaging. 2006 Jul;33(7):823-30
pubmed: 16570185
J Nucl Med. 2009 Mar;50(3):426-34
pubmed: 19223422
J Clin Invest. 2005 Feb;115(2):339-47
pubmed: 15668738
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
pubmed: 18287387